节点文献

信必可都保联合孟鲁司特治疗稳定期中重度COPD疗效观察

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 彭毅斌

【机构】 广东省梅州市人民医院呼吸一科

【摘要】 目的研究信必可都保以及孟鲁司特对稳定期的中重度慢性阻塞性肺疾病COPD疾病的疗效情况。方法 2012年3月~2013年3月于广东省梅州市人民医院共计有86例患者被确诊为稳定期的中重度COPD疾病。以数字法随机均分成观察组(n=43)和对照组(n=43)。对比2组疗效以及不良反应情况。结果观察组治疗之后的FEV1为(1.59±0.55)L、FEV1%为(56.33±0.65)%,FEV1/FVC为(61.95±0.45)%,均显著高于治疗之前的(1.46±0.42)L、(43.79±0.62)%、(52.64±0.45)%,以及对照组治疗之后的(1.46±0.67)L、(46.28±0.62)%、(56.74±0.51)%;观察组治疗之后的6-MWD为(226.08±18.5)m,显著大于治疗之前的(180.55±16.8)m,以及对照组治疗之后的(185.25±19.9)m;呼吸困难的评分为(2.05±0.62)分,均显著低于治疗之前的(3.04±0.24)分,以及对照组治疗之后的(2.97±0.58)分,差异均有统计学意义(均P<0.05)。治疗12周之后,观察组有2例口咽部不适,1例头痛,1例心悸;对照组1例口咽部不适,1例心悸。2组差异无统计学意义。结论信必可都保药物与孟鲁司特药物联用,加以治疗稳定期的中重度COPD疾病,疗效较为显著,值得临床推荐。

【Abstract】 Objective To study the clinical effect of budesonide and formoterol fum arate powder for inhalation combined montelukast for treatment of stable phase of moderate and severe COPD. Methods 86 patients with diagnosed stable phase of moderate and severe COPD were randomly divided into observation group and control group both with 43 cases. Clinical effects and Adverse reactions conditions of the 2 groups were compared. Results FEV1, FEV1% and FEV1/FVC of observation group after treatment were respectively(1.59±0.55)L,(56.33±0.65)% and(61.95±0.45)% which were all obviously higher than before treatment(1.46±0.42) L,(43.79±0.62)% and(52.64±0.45)% and control group after treatment(1.46±0.67)L,(46.28±0.62)% and(56.74±0.51)%; 6-MWD was(226.08±18.5)m which was obviously larger than before treatment(180.55±16.8)m, and than control group after treatment(185.25±19.9)m; dyspnea score was(2.05±0.62) which was obviously lower than before treatment(180.55±16.8)m and than control group after treatment(2.97±0.58)(P<0.05). After 12 weeks of treatment, there were 2 oropharyngeal discomfort, 1 headache and 1 palpitation in observation group while 1 oropharyngeal discomfort and 1 palpitation in control group. ConclusionBudesonide and formoterol fum arate powder for inhalation combined montelukas for treatment of stable phase of moderate and severe COPD has a signifi cant clinical effect and is worth of being recommended clinically.

  • 【文献出处】 当代医学 ,Contemporary Medicine , 编辑部邮箱 ,2014年13期
  • 【分类号】R563.9
  • 【被引频次】7
  • 【下载频次】35
节点文献中: